UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

         Date of Report (Date of earliest event reported): Jume 30, 2003

                           APPLIED DNA SCIENCES, INC.
                      ------------------------------------
             (Exact name of registrant as specified in its charter)


           Nevada                         2 90519            59-2262718
           ------                         -------            ----------
(State or other jurisdiction            Commission         (IRS Employer
    of Incorporation)                   File Number      Identification No.)


                9225 Sunset Boulevard Los Angeles, CA      90069
               ---------------------------------------- ----------
               (Address of principal executive offices) (Zip Code)


       Registrant's Telephone Number, including area code: (310) 860-1362



         (Former name or former address, if changed since last report.)





Item 5.  Other Information

On or about June 9, 2003,  Applied DNA Sciences,  Inc.  ("the  Company")  made a
repurchase of 7,500,000  shares of its common stock by partially  exercising its
option  with  Glenn   Little,   the  former   president  of  ProHealth   Medical
Technologies,  Inc.  Subsequent  to the Company's  reorganization  in October of
2002,  Glenn  Little  granted  a one year  option  to the  Company  to  purchase
8,500,000 common shares held in his name for $100,000. For the Company's partial
exercise,  Glenn Little accepted a convertible  promissory note in the amount of
$88,500.  On June 30, 2003 the Company returned the shares to its stock transfer
agent  for  cancellation.   Glenn  Little  disclosed  the  transaction  and  his
disposition of shares on a Form 4.

The number of shares issued and  outstanding as a result of this  transaction is
16,936,722.


Exhibit
-------

99.3     Promissory Note.


SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.



                                        APPLIED DNA SCIENCES, INC.


                                        /s/ Gerhard H. Wehr
                                        ------------------------------
                                        Gerhard H. Wehr
                                        Chief Financial Officer